How effective is venetoclax treated

In 2016, the drug was circulated on the market, and there are three specifications of 10mg, 50mg, and 100mg. Venetoclax is currently the only apoptosis drug developed based on apoptosis mechanism approved for marketing in the world, and is a selective inhibitor of Bcl-2 (BCL-2 protein, as an important regulatory component of apoptosis, is widely present and highly expressed in tumor cells).

To find out how effective venetoclax is, we will use AML (acute myeloid leukemia) as an example.

At present, the treatment of AML is mainly based on strong induction chemotherapy, but due to the poor constitution and poor tolerance of some cases, the prognosis is poor, and the survival time and quality of life of patients are not high. And this problem has been solved after the marketing of venetoclax, which fills the treatment gap in this part.

Bcl-2 (B-cell lymphoma factor-2) helps cancer cells live longer and is the main oncogene for most hematologic cancers, and there are other genetic mutations that make treatment more difficult in AML patient examination reports. But venetoclax can cross this barrier and act directly on Bcl-2 and exert an inhibitory effect.

This shows that venetoclax is a breakthrough treatment, and what is even more exciting is that the treatment effect is also very significant. After comparing the effect of azacitidine in the treatment of AML with venetoclax in combination with venetoclax in the treatment of AML, the response rate of azacitidine plus venetoclax in the treatment of AML was 50% higher than that of azacitidine alone.

In addition, the complete response rate was also as high as 66.4%, which was significantly higher than the response rate of azacitidine monotherapy (28.3%). It can be seen that whether it is the efficacy or the plan, venetoclax is very valuable in the treatment of blood diseases!

Venetoclax not only marks the beginning of the era of targeted therapy, but also brings hope for survival to many patients. However, individualized treatment plans need to be developed for different conditions, so it is recommended that patients with blood patients undergo a detailed assessment of their condition rather than blindly selective medication.